Gilead Sciences balked at licensing the U.S. government’s HIV-prevention patent rights, and now the feds are striking back. HHS sued Gilead for patent infringement Wednesday, saying the company and its HIV prophylaxis meds Truvada and Descovy reaped profits off hundreds
read moreAfter a successful partnership with its biosimilar joint venture Samsung Bioepis, Biogen has decided to move into more drugs and markets. In an expanded deal, Biogen is putting down $100 million up front for copycats to Novartis and Roche’s Lucentis,
read moreIn an offer aimed at settling the thousands of opioid lawsuits it faces, Teva has proposed an eye-popping $23 billion-plus deal with plaintiffs. So far, that offer hasn’t gained much traction, though, leaving the drugmaker with a legal overhang that now tops 10 figures.
read moreForthcoming migraine meds from Eli Lilly, Allergan and Biohaven took some hits in ICER’s new data review. While they’re clearly better than placebo, the new drugs don’t beat existing triptan treatments, ICER figures, except in patients who haven’t seen relief
read moreCosette Pharmaceuticals was formed last year when it picked up the dermatology business and a creams and topicals manufacturing plant of G&W Laboratories. Now, Cosette has gone back for another of G&W’s manufacturing facilities. More: Cosette to add liquids to
read moreThe jointly-sponsored study aims to validate PredictSURE IBD – the company’s first prognostic test for inflammatory bowel disease, in the US market. More: PredictImmune announces PredictSURE IBD study Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals